Investment Rating - The report initiates coverage with a "Strong Buy" rating for the company [1][11]. Core Insights - The company is positioned as a leader in the dual antibody market, specifically PD-1/VEGF, showcasing potential that surpasses existing therapies like K drug. The year 2026 is critical for validating core clinical data and achieving profitability through commercialization [1][15]. - The success of the HARMONi-2 trial indicates that the PD-1/VEGF dual antibody could replace existing therapies, marking a significant advancement in immunotherapy [7][17]. - The company is expected to lead the next generation of immuno-oncology therapies, with multiple key clinical data readouts anticipated in 2026-2027 that could significantly impact its stock price [26][30]. Summary by Sections Section 1: Company Overview - The company is the only global entity with two tumor immune dual antibody drugs, leading the upgrade of immunotherapy [15]. - The PD-1/VEGF dual antibody development is gaining momentum, with several significant transactions indicating a robust market interest [15][21]. Section 2: AK112 Developments - AK112 is set to read out multiple critical data points in 2026-2027, which are pivotal for the company's growth and international expansion [26][32]. - The HARMONi-6 and HARMONi-3 trials are expected to reshape the competitive landscape for first-line squamous non-small cell lung cancer (sq-NSCLC) [7][30]. - The interim data from HARMONi-3 and HARMONi-6 in 2026 will be crucial for stock price movements [27][28]. Section 3: AK104 Developments - AK104 fills a clinical gap in immune treatment for gastric cancer and cervical cancer, achieving significant breakthroughs in these areas [11][32]. - The potential market for AK104 in first-line gastric cancer treatment is estimated to reach $5.2 billion, with additional opportunities in hepatocellular carcinoma (HCC) [11][32]. Section 4: Research Pipeline and Clinical Efficiency - The company has a rich pipeline and efficient clinical processes that drive continuous growth in the biopharma sector [11][32]. - The company is advancing multiple clinical trials, including collaborations with external partners to explore combination therapies [8][32]. Section 5: Financial Forecast and Investment Rating - The company is projected to achieve revenues of 47.38 billion, 72.12 billion, and 95.85 billion yuan from 2026 to 2028, with significant year-on-year growth [10][11]. - The report maintains a "Strong Buy" rating based on the anticipated financial performance and market potential [11][32].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for the stock over the next six months [11]. Core Insights - The company reported a revenue of 3.056 billion yuan for 2025, representing a year-on-year growth of 43.9%, with commercial sales revenue increasing by 51.5% [2][3]. - The inclusion of two innovative dual-antibody drugs, Cardunili and Ivorosi, in the national medical insurance directory has significantly boosted sales [2][3]. - The company has expanded its sales team to approximately 1,300 personnel, focusing on oncology and specialty drugs [3]. - Clinical data for core products continues to validate their global competitiveness, with Ivorosi achieving significant results in lung cancer treatment [3]. - The company is advancing its "IO2.0 + ADC2.0" strategy, with new products in the autoimmune metabolism field and ongoing clinical trials for next-generation ADC drugs [4]. Financial Summary - The company expects revenues of 5.161 billion yuan, 7.106 billion yuan, and 8.752 billion yuan for 2026, 2027, and 2028, respectively, with net profits projected at 244 million yuan, 1.111 billion yuan, and 1.569 billion yuan [4][6]. - The EBITDA loss for 2025 was 192 million yuan, a reduction from 241 million yuan in the previous year [2][3]. - The company’s gross margin is expected to improve, reaching 82.0% by 2028 [12].

Group 1: 康方生物 - Company maintains a "Buy" rating for 康方生物 with a target price of HKD 185.80, expecting product sales revenue to reach HKD 3 billion in 2025, a 52% year-on-year increase, driven by Cadonilimab and Ivonescimab entering the national medical insurance directory [1] - Ivonescimab has shown significant improvement in progression-free survival in head-to-head Phase III clinical trials, with key global data readout imminent [1] - The FDA review target date for EGFR-TKI resistant NSCLC indication is set for November 2026, potentially marking the company's first FDA-approved product [1] Group 2: 中国铁塔 - Company maintains a "Hold" rating for 中国铁塔 with a target price of HKD 12.10, projecting a 2.7% revenue growth to HKD 100.4 billion in 2025, and an 8.4% net profit increase to HKD 11.6 billion [1] - Revenue from the communication tower business is expected to decline by 0.3% year-on-year due to continued capital expenditure reductions from the three major operators [1] - DAS and "two wings" businesses are anticipated to maintain double-digit growth, contributing to revenue diversification [1] Group 3: 信达生物 - Company maintains a "Buy" rating for 信达生物 with a target price of HKD 113.86, forecasting a first-time annual profit of HKD 834 million in 2025, with product sales revenue reaching HKD 11.9 billion, a 45% year-on-year increase [2] - Key growth drivers include newly launched products Mazdutide, PCSK9 monoclonal antibody, and IGF-1R antibody [2] - Collaboration with Takeda to advance IBI363 into global Phase III clinical trials, with multiple assets entering or nearing global multi-center Phase III [2] Group 4: TCL电子 - Company maintains a "Buy" rating for TCL电子, expecting 2025 revenue of HKD 114.6 billion, a 15.4% year-on-year increase, and a net profit of HKD 2.5 billion, a 41.8% increase [3] - Growth is primarily driven by a 15.7% increase in overseas television revenue, a doubling of Mini LED shipments, and a 63.6% surge in photovoltaic business revenue [3] - Joint venture with Sony is imminent, expected to enhance high-end channel access and improve profitability [3] Group 5: 小马智行-W - Company maintains a "Buy" rating for 小马智行-W with a target price of HKD 195, projecting a 129% year-on-year increase in Robotaxi revenue in 2025 [4] - Achieved positive unit economics in Guangzhou and Shenzhen, with peak daily revenue per vehicle reaching HKD 394 [4] - The BOM cost of the seventh-generation model has decreased by 20% compared to the previous generation, with plans to expand the fleet to 3,000 vehicles [4] Group 6: 优然牧业 - Company maintains a "Buy" rating for 优然牧业, forecasting a 13.2% increase in raw milk sales volume to 4.15 million tons in 2025, with per cow production rising to 12.8 tons/year [5] - Feed cost per kilogram of milk is expected to decrease by 10.5%, with cash EBITDA reaching HKD 5.59 billion, a 4.9% year-on-year growth [5] - Anticipation of a dual-cycle resonance point for milk and meat prices in 2026 due to ongoing industry capacity reduction and rising beef prices [5] Group 7: 移卡 - Company maintains an "Outperform" rating for 移卡 with a target price of HKD 8.90, projecting a domestic payment rate increase to 12.3 bps and a 3.2-fold increase in overseas GPV to HKD 4.7 billion in 2025 [6] - This growth is expected to drive an 8% increase in acquiring revenue [6] - Integration of AI throughout the operational process has led to a 13% reduction in sales and management expenses, with core EBITDA growing by 53% to HKD 350 million [6] Group 8: 中国民航信息网络 - Company maintains a "Buy" rating for 中国民航信息网络 with a target price of HKD 15.70, expecting a 4.9% growth in aviation information technology processing volume and an 18.8% increase in revenue from smart travel products and services in 2025 [7] - Revenue from airport digital services is projected to decline by 20.8% due to construction schedule impacts, but significant cost reductions in depreciation and amortization are expected to enhance operating profit margins by 3.6 percentage points to 30.9% [7] Group 9: 碧桂园服务 - Company maintains an "Accumulate" rating for 碧桂园服务 with a target price of HKD 7.24, forecasting a 10% revenue growth to HKD 48.35 billion in 2025, while core net profit is expected to decline by 17% to HKD 2.52 billion [8] - The decline is attributed to pressure on community value-added services and increased impairment of receivables [8] - Annualized revenue growth from market expansion is projected to reach 87% to HKD 2.03 billion, with a significant increase in shareholder returns, raising the dividend payout ratio to 60% [8] Group 10: 赤子城科技 - Company maintains an "Accumulate" rating for 赤子城科技, projecting a 32.9% year-on-year increase in social business revenue to HKD 6.14 billion in 2025 [9] - Revenue from SUGO and TopTop is expected to grow by over 80% and 70%, respectively, with rapid expansion in emerging markets such as Latin America and Japan [9] - Innovative business revenue is projected to grow by 59.3%, driven by the launch of AI self-developed models Boomiix and creative community Aippy, forming a second growth curve through "diversified matrix + global expansion" [9]

Investment Rating - The report indicates a positive outlook on the Chinese innovative drug industry chain, with a focus on business development (BD), policy, and clinical advancements [1]. Core Insights - The innovative drug BD authorization total exceeded $60 billion in Q1 2026, reflecting accelerated global cooperation value [2][11]. - The Chinese government has upgraded its strategic positioning of the biopharmaceutical industry, marking it as a "new emerging pillar industry" in the 2026 government work report [2][15]. - Clinical activity is on the rise, with Chinese innovative drug R&D entering a high-quality harvest period, as evidenced by a significant increase in the number of innovative drugs entering clinical trials and being approved for market [2][16][19]. Market Observation - The pharmaceutical and biotechnology sector rose by 1.56% this week, ranking 4th out of 31 sectors, while it has seen a year-to-date decline of 1.38%, ranking 17th [1][10]. Industry Dynamics - In 2025, the total transaction amount for Chinese innovative drug BD reached a historical high of $135.655 billion, with 157 transactions, and the first quarter of 2026 has already seen over $60 billion in transactions [2][11]. - The first version of the commercial health insurance innovative drug catalog was officially launched, enhancing the multi-layered payment system for innovative drugs [2][15]. - By the end of 2025, China accounted for 33.7% of the global innovative drugs in development, leading the world, with 827 innovative drugs entering clinical trials for the first time [2][16][19]. Company Dynamics - **Insilico Medicine**: Announced a collaboration with Eli Lilly, with an upfront payment of $115 million and a total deal value of up to $2.75 billion, validating the commercial potential of its AI drug development platform [3][23]. - **Kangfang Biopharma**: Achieved revenue of 3.056 billion yuan in 2025, a year-on-year increase of 43.9%, driven by core dual-antibody products [3][24]. - **Innovent Biologics**: Reported total revenue of 13.042 billion yuan in 2025, a 38.4% increase, marking its first year of profitability with a significant growth in product revenue [3][25]. - **Kolin Biotech**: Generated revenue of 2.058 billion yuan in 2025, with a focus on the commercialization of its core ADC products [3][26]. - **Ascletis Pharma**: Achieved record revenue of 7.731 billion yuan in 2025, with innovative drugs accounting for 81.5% of total revenue [3][27]. - **Zai Lab**: Reported revenue of 269.6 million yuan in 2025, with a strong cash reserve of 919 million yuan, supporting its global expansion plans [3][28].

Summary of the Conference Call for Kangfang Biopharma Company Overview - **Company**: Kangfang Biopharma - **Date**: March 27, 2026 Key Industry and Company Insights 1. Product and Market Access Achievements - In 2025, all five products of Kangfang Biopharma, covering 12 indications, were successfully included in the national medical insurance directory, significantly supporting sales growth in 2026 [2][5] - The commercial revenue for 2025 reached 3.033 billion yuan, marking a 51% increase year-on-year, primarily driven by two dual-antibody products [3][29] - The company expanded its commercial team to 1,500 people, doubling from approximately 800 in 2024, and achieved a 90% hospital access rate for its dual-antibody products [3][4] 2. Clinical Development and Product Pipeline - **Ivosidenib (PD-1/VEGF)**: Currently involved in 15 global Phase III clinical trials, with significant results expected in 2026. It is the only PD-1/VEGF dual antibody approved in the U.S. and has benefited around 70,000 patients [6][12] - **Kadonil (PD-1/CTLA-4)**: Demonstrated significant overall survival (OS) advantages in PD-L1 negative populations and is undergoing Phase III trials for first-line gastric cancer [6][15][17] - **Immunology Products**: The first self-developed product, Inokizumab (IL-12/23), was approved in 2025 for psoriasis and included in the national insurance directory [8] 3. Financial Performance - Total revenue for 2025 was 3.056 billion yuan, with a cash reserve of 9 billion yuan, indicating a strong financial position [29] - R&D expenditure was 1.575 billion yuan, with a decreasing R&D intensity ratio from 78% in 2023 to 52% in 2025, aiming for a target of around 25% [29] - The adjusted EBITDA loss narrowed to 191 million yuan, compared to a loss of 241 million yuan in 2024, reflecting improved financial health [29] 4. Strategic Collaborations and Future Plans - The company has partnered with Jichuan Pharmaceutical for the commercialization of its PCSK9 antibody, optimizing sales efficiency through external collaboration [10] - Future product launches are planned, with expectations for ten new products and over 25 indications in the next five years [31] 5. Technological Advancements - The company is upgrading its technology platform to "IO 2.0 + ADC 2.0," focusing on combining dual antibodies with antibody-drug conjugates (ADCs) to lead the next generation of cancer immunotherapy [4][11] - AI technology is being integrated across various business operations to enhance efficiency and quality in drug development [30][32] 6. Clinical Milestones and Regulatory Progress - Significant clinical milestones were achieved in 2025, including positive results from the HARMONi-A and HARMONi-3 studies, which are expected to enhance the credibility of Chinese innovative drugs in international markets [13][14] - The company is actively preparing for further international clinical trials and regulatory submissions, particularly for Ivosidenib and Kadonil in various indications [33][34] Additional Important Insights - The dual-antibody products are positioned as foundational therapies for future cancer treatment paradigms, with ongoing studies exploring their combination with ADCs and other novel therapies [19][28] - The company is also exploring innovative treatments in autoimmune diseases and central nervous system disorders, leveraging its dual-target antibody platform [21][22] This summary encapsulates the key points from the conference call, highlighting the company's achievements, strategic direction, and future outlook in the biopharmaceutical industry.

Summary of Conference Call Records Industry Overview - The focus is on the oral GLP-1 drug "O Drug" and its related supply chain, with companies like Kanglong Chemical, WuXi AppTec, Kelun Pharmaceutical, and Chengda Pharmaceutical receiving clear orders for production [1][2] - The global biotech sector is shifting from monetary policy influences to breakthroughs in technology and patent cliffs, with expectations for a similar upward cycle as seen in 2014/2018 driven by GLP-1 products and M&A demands [1][3] - The domestic innovative drug sector is showing positive fundamentals, with business development (BD) totals reaching levels comparable to the first half of 2025, indicating a transition from losses to profitability for many companies [1][4] Key Points on "O Drug" - "O Drug" is expected to receive FDA approval for weight loss indications in April 2026, with its application submitted at the end of 2025 [2] - A head-to-head study in February 2026 showed "O Drug" outperforming oral semaglutide in reducing glycated hemoglobin and weight loss [2] - The product is currently in a pre-approval stocking phase, which is anticipated to boost API and CDMO orders for companies involved in its production [2] Market Dynamics - The current macro environment for the global biotech industry is driven by technological breakthroughs and the impending patent cliffs faced by large pharmaceutical companies, leading to increased M&A activity [3][4] - Historical data indicates that biotech indices have continued to rise even during interest rate hikes, suggesting a resilient market [4] Investment Opportunities - The investment strategy emphasizes selecting companies transitioning from biotech to biopharma, with Kangfang Biologics and Kangnuo Pharmaceutical highlighted for their expected sales growth and pipeline flexibility [1][7] - A tiered investment approach is recommended: - **Low-risk, high-certainty companies**: Kangfang, Kangnuo, and Fuhong Hanlin are expected to have significant growth potential [1][7] - **High-flexibility companies**: Companies like Junshi Biosciences and Xinlitai are noted for their potential to double or triple in value based on performance [1][7] - **Stable companies**: Companies such as Baiji Shenzhou and Xinda Biopharmaceuticals are recommended for long-term holding with expected growth of 30% to 50% [1][7] Emerging Technologies - The core focus for Chinese innovative drugs going abroad in 2026 includes dual antibodies (e.g., PD-1/VEGF) and ADCs, with significant clinical data expected to validate their market potential [6] - New technologies such as TCE dual antibodies and small nucleic acid drugs are also highlighted for their promising development and potential for international transactions [6] Conclusion - The innovative drug sector is positioned for growth, supported by favorable policies and a recovering market valuation after significant corrections in leading company stock prices [5][6]

Summary of Key Points from Conference Call Records Industry Overview - **Industry Focus**: Innovative pharmaceuticals, particularly in the context of China's biopharmaceutical sector and its international expansion - **Market Growth**: The total value of BD (Business Development) transactions for innovative drugs is projected to reach $137.7 billion by 2025, a 1.6 times increase year-on-year, significantly surpassing the electric vehicle sector's $74 billion in the same timeframe [1][2][3] Core Insights and Arguments - **International Expansion**: The innovative drug sector is experiencing explosive growth in international markets, with Q1 2026 BD transactions already reaching $60 billion, accounting for 46% of the total for 2025 [1][2] - **Policy Support**: Biopharmaceuticals have been designated as a new pillar industry by the Chinese government, shifting focus from public welfare to GDP contribution, indicating a supportive policy environment for growth [2][3] - **Performance Expectations**: Companies like Heng Rui Medicine are expected to see over 30% growth in innovative drug revenue by 2026, with significant contributions from key products [1][3] - **Clinical Developments**: Major clinical data releases are anticipated from key conferences such as AACR and ASCO, which could catalyze market movements [1][5] Notable Companies and Their Prospects - **Heng Rui Medicine**: Expected to achieve over 30% growth in innovative drug revenue, with a strong pipeline of 53 products anticipated for approval between 2022 and 2028 [15] - **Kangfang Biopharma**: Key product AK112 is set to release critical clinical data in 2026, which could significantly impact its market position [11][13] - **Baiyi Shenzhou**: Projected profits of $700-800 million in 2026, indicating a rapid profit climb [1][8] - **Xinda Biopharma**: Anticipated to benefit from new product approvals and commercial launches, with a focus on expanding its product pipeline [6][8] Investment Opportunities - **Recommended Stocks**: Key investment targets include Kangfang Biopharma, Xinda Biopharma, Baiyi Shenzhou, and Kelong Biotechnology in the H-share market, and Xintai, Haishike, and Heng Rui Medicine in the A-share market [4][8] - **Undervalued Stocks**: Companies like Hot Scene Biopharma and Yifang Biopharma, which have seen significant price declines, are suggested for bottom-fishing opportunities [4][8] Emerging Trends - **Small RNA Technology**: The small RNA sector is entering a critical phase with breakthroughs in liver-targeted delivery technologies, and several companies are expected to announce significant clinical data in 2026 [18][22] - **Clinical Data Impact**: Recent clinical data from companies like Serapta and Wave Life Sciences highlight the potential and challenges within the small RNA space, influencing market sentiment and investment strategies [20][21] Conclusion - The innovative pharmaceutical sector in China is poised for significant growth driven by international expansion, supportive policies, and strong company performances. Key clinical events and emerging technologies present substantial investment opportunities, particularly in small RNA and innovative drug development.

Investment Rating - The report maintains a BUY rating for Akeso with a target price of HK$185.80, representing a 47.0% upside from the current price of HK$126.40 [3][9]. Core Insights - Akeso delivered strong product sales of RMB3.0 billion in FY25, reflecting a 52% year-over-year growth, closely aligning with previous estimates of RMB3.1 billion. This growth was primarily driven by the inclusion of cadonilimab and ivonescimab in the NRDL in January 2025 [1][2]. - Revenue growth is expected to accelerate further in FY26, supported by additional NRDL inclusions for major front-line indications [1]. - The company demonstrated operational leverage, with selling and R&D expenses as a percentage of product sales decreasing to 47% and 51%, respectively, from 49% and 56% in FY24 [1]. - Despite a reported net loss of RMB1.14 billion in FY25, Akeso maintains a robust balance sheet with RMB9.2 billion in cash and equivalents, providing a strong foundation for its late-stage clinical programs [1][2]. Financial Summary - Revenue projections for FY26 are estimated at RMB5.01 billion, with a year-over-year growth of 63.9%, followed by RMB8.68 billion in FY27 and RMB11.46 billion in FY28 [2][13]. - The net profit is projected to improve to RMB725.3 million in FY27 and RMB1.63 billion in FY28, after a loss of RMB733.7 million in FY26 [2][13]. - The gross profit margin is expected to normalize to 79% in FY25, down from 86% in FY24, due to price cuts associated with NRDL inclusions [1][2]. Clinical Development and Strategic Initiatives - Akeso is anticipating pivotal data readouts for ivonescimab, which has already met its primary PFS endpoint in a Phase 3 trial, showing a median PFS of 11.1 months compared to 6.9 months for the comparator [1][9]. - The company is advancing the global footprint of cadonilimab through pivotal trials, including a global Phase 2 trial for IO-resistant 2L HCC and a Phase 3 trial for 1L GC [1][9]. - Akeso's strategy includes the development of proprietary ADCs, with ongoing Phase 2 trials for HER3 ADC and TROP2/Nectin-4 ADC, aiming to evaluate combinatorial regimens with existing therapies [1][9].

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [1] Core Insights - The pharmaceutical sector has shown resilience, with the innovative drug segment leading a rebound, driven by positive industry dynamics and market sentiment [7][10] - The report emphasizes the potential for continued growth in innovative drugs, supported by favorable government policies and strong performance in recent financial disclosures from biotech and biopharma companies [7][10] - The long-term care insurance (LTCI) policy in China is expected to accelerate the development of the elderly care industry, drawing parallels with Japan's successful model [10][23] Summary by Sections 1. Long-term Care Insurance and Elderly Care Industry - The Chinese government aims to establish a long-term care insurance system within three years, initially covering employees, retirees, and gradually including unemployed rural residents [10] - The LTCI system is designed to alleviate the financial burden on families and improve care for the elderly, with a focus on home and community care [10][23] - Investment opportunities in the elderly care sector include home medical devices, rehabilitation equipment, and elderly care institutions [23] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical index increased by 1.56% during the week of March 23-27, outperforming the ChiNext and CSI 300 indices [24] - The overall trading volume for pharmaceuticals was 449.11 billion yuan, accounting for 4.28% of the total market, below the historical average of 7.06% [46] - The report highlights the strong performance of innovative drugs, with companies like Meinuohua and Wanbangde leading the gains [49] 3. Investment Recommendations - The report suggests focusing on companies involved in the overseas big pharma BD 2.0 phase, such as Kelun Pharmaceutical and Xinlitai, as well as small and mid-cap biotech firms with innovative technologies [7][23] - It also recommends monitoring the supply chain and technology sectors, including CROs and CDMOs, as they are expected to benefit from ongoing industry trends [7][23]

Financial Performance - For the fiscal year ending December 31, 2025, the total revenue of Akeso, Inc. was RMB 3,056.3 million, representing a year-on-year increase of 43.9% from RMB 2,123.9 million in 2024[7]. - The gross profit for the fiscal year ending December 31, 2025, was RMB 2,404.0 million, up 31.01% from RMB 1,834.9 million in 2024[8]. - The company reported a net loss of RMB 1,140.8 million for the fiscal year ending December 31, 2025, which included non-cash items such as a loss of RMB 324.8 million related to long-term equity investments[9]. - The adjusted Non-IFRS net loss for 2025 was RMB 584.7 million, with an adjusted Non-IFRS EBITDA loss of RMB 191.9 million[9]. - Revenue for the reporting period was approximately RMB 3,056.3 million, a 43.90% increase from RMB 2,123.9 million in the same period last year[13]. - The company reported a total net loss of RMB 1,166,824,000 for the year, compared to a net loss of RMB 494,503,000 in the previous year, indicating a significant increase in losses[114]. - Basic loss per share for 2025 is RMB 1.23, compared to RMB 0.60 in 2024, reflecting a deterioration in earnings performance[114]. Commercial Sales and Product Development - Commercial sales revenue for the fiscal year ending December 31, 2025, was RMB 3,033.1 million, a 51.48% increase from RMB 2,002.4 million in 2024, driven by new product approvals[7]. - The company successfully introduced two innovative bispecific antibodies into the National Reimbursement Drug List (NRDL), contributing to revenue growth[6]. - The company has over 50 innovative projects under research, covering areas such as tumors, autoimmune diseases, metabolism, and neurodegenerative diseases[12]. - The company has 27 products in the market or clinical research stages, with 12 in Phase III clinical trials and 15 in Phase I/II trials[12]. - Five self-developed commercialized drugs have received approval for 12 indications, all included in the 2025 version of the national medical insurance catalog, to be implemented in January 2026[14]. - The product IYINING® (Inepolog) has been approved for two indications in China, both included in the latest national medical insurance catalog[17]. - The product YIDAFANG® (Ivosidenib) has completed over 44 clinical studies, including 15 Phase III trials, with positive results in four Phase III trials covering multiple cancer types[16]. Research and Development - The company has established a comprehensive R&D platform focusing on innovative antibody drug development technologies, positioning itself competitively in the global biopharmaceutical market[11]. - Akeso, Inc. is advancing multiple new bispecific antibodies into clinical research, including ADCs and treatments for immune-related diseases[5]. - The company aims to enhance its financial performance while increasing R&D investments to support future growth[5]. - The company is actively expanding into cold tumors and has initiated multiple clinical studies covering colorectal cancer, pancreatic cancer, cholangiocarcinoma, head and neck squamous cell carcinoma, and triple-negative breast cancer[22]. - The company is advancing multiple self-developed products in oncology, autoimmune diseases, and Alzheimer's disease, including AK139, AK152, and AK150, currently in Phase I and II clinical trials[64]. Clinical Trials and Approvals - The clinical study (AK112-306/HARMONi-6) for the combination therapy of Ivoris and Tarelizumab achieved the primary endpoint of progression-free survival (PFS) for sq-NSCLC, with results presented at the 2025 ESMO LBA[23]. - The international multicenter III phase clinical study (HARMONi) for Ivoris in treating NSCLC after third-generation EGFR-TKI therapy reached the PFS primary endpoint, with significant overall survival (OS) trends[24]. - The combination therapy of Ivoris and chemotherapy for PD-L1 negative TNBC entered the III phase clinical study (AK112-308), which received breakthrough therapy designation from NMPA in November 2025[26]. - The company has initiated nearly 20 combination clinical studies for Ivoris in China, focusing on various cancer types such as lung, gastric, and colorectal cancers[28]. - The company received FDA approval for the international multicenter Phase III clinical study (COMPASSION-37) of cardunili combined with chemotherapy for the treatment of unresectable or metastatic G/GEJ adenocarcinoma, officially launched in December 2025[34]. Financial Position and Assets - As of December 31, 2025, the company's current assets totaled RMB 11,277.3 million, with cash and cash equivalents amounting to RMB 9,171.6 million[87]. - The company's current liabilities as of December 31, 2025, were RMB 2,195.1 million, which included trade payables of RMB 451.8 million[87]. - The company had short-term and long-term loans totaling RMB 4,540.6 million, with short-term loans due within one year amounting to RMB 585.7 million[88]. - The company's total assets amounted to RMB 13,805,313,000 in 2025, compared to RMB 11,068,335,000 in 2024, reflecting an increase of approximately 24.9%[115]. - The company’s inventory increased to RMB 931,616,000 in 2025 from RMB 706,533,000 in 2024, showing a growth of about 31.7%[115]. Employee and Corporate Governance - As of December 31, 2025, the total number of employees has grown to 3,761, with significant increases in clinical research and development personnel to support the integrated platform strategy[57]. - The company has adhered to all corporate governance code provisions during the reporting period, except for provision C.2.1, which states that the roles of chairman and CEO should be separate[101]. - The company issued a total of 23,550,000 new shares at a price of HKD 149.54 per share on September 4, 2025, representing approximately 2.56% of the enlarged issued share capital post-placement[105]. Strategic Goals and Future Outlook - The company aims to become a global leader in biopharmaceuticals by focusing on innovative drug development and establishing an international standardized production system[13]. - The company is actively expanding its international development strategy, aiming to advance more self-developed innovative drugs in the global market[67]. - The company is focused on maximizing the global value of its core products, including Ivosidenib, which has shown significant clinical benefits in multiple Phase III studies[63].